Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.


Message from the President

I, Yoshifumi Torii, was appointed as President and CEO of Fujifilm Kyowa Kirin Biologics Co., Ltd, effective October 1, 2017.
We will always offer top-grade, reasonably priced, therefore highly reliable biosimilar pharmaceuticals to contribute to the world.

[photo]Hideaki Nomura,President & CEO

FUJIFILM KYOWA KIRIN BIOLOGICS was launched in March 2012 to develop and meet the global demand for biosimilars, also known as subsequent entry biologics. Due to the particular requirements of biopharmaceuticals, development requires specialized expertise and know-hows, while production demands the use of advanced techniques and facilities. The combination of the technology and know-hows that have been accumulated by Kyowa Hakko Kirin through its R&D and productions in the biomedical field, and the engineering, manufacturing, quality-management and analytical skills that have been honed by Fujifilm Corporation through its wide-ranging businesses, has enabled us to achieve a top level of quality and create an innovative production process that will reduce the production costs.

Healthcare costs have risen recently, particularly in developed countries, due to ageing populations and the emergence of highly effective, yet highly expensive, medicines such as biopharmaceuticals. These rising costs are a burden on those countries’ finances. As the situation is likely to escalate in the future, we hope to contribute to containing rising healthcare costs by making biosimilars available as less-pricey biopharmaceuticals.

In 2017, Marketing Authorisation Application (MAA) for FKB327, an Adalimumab biosimilar candidate, was accepted for review by the European Medical Agency (EMA).
At the same time, we are preparing for Biologics License Application (BLA) of FKB327 for the U.S. Food and Drug Administration (FDA).
We are also developing our next product FKB238, a Bevacizumab biosimilar candidate, which is under a Phase 3 global clinical study.

We will continue to commit all our effort to promptly provide superior quality products at the lowest possible cost, always considering those patients who shall be using them. We are committed to continuously advancing the development of biosimilars so we can deliver them as early as possible to the right patients. We greatly appreciate your continued support and encouragement in our ongoing mission.

Yoshifumi Torii, Ph.DPresident & CEO

Text Size


  • Biosimilar
  • Solution
  • Message

Group Companies

Contact us


Back to Top